D.E. Shaw & Co
NVLN

D.E. Shaw & Co’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

D.E. Shaw & Co’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-29,417
Closed -$103K – 3983
2018
Q1 		$103K Sell
29,417
-10,790
-27% -$45.7K ﹤0.01% 3387
2017
Q4 		$125K Buy
40,207
+4,230
+12% +$20.3K ﹤0.01% 3480
2017
Q3 		$253K Buy
35,977
+6,878
+24% +$55.1K ﹤0.01% 3208
2017
Q2 		$269K Sell
29,099
-18,421
-39% -$177K ﹤0.01% 3071
2017
Q1 		$510K Sell
47,520
-25,000
-34% -$255K ﹤0.01% 2726
2016
Q4 		$611K Buy
+72,520
New +$642K ﹤0.01% 2739

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

D.E. Shaw & Co's NVLN Position: Q2 2018 in Review

D.E. Shaw & Co sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q2 2018, closing a stake of 29,417 shares — an estimated $103K sold.

D.E. Shaw & Co first reported a position in NVLN in Q4 2016 and held it in 6 quarters. The position peaked at $611K in Q4 2016. 53 funds tracked by Wall St. Rank hold NVLN as of Q2 2018.

  • D.E. Shaw & Co reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q2 2018 after selling out during the quarter.
  • D.E. Shaw & Co sold 29,417 Novelion Therapeutics Inc. Common Shares shares in Q2 2018, an estimated $103K.
  • D.E. Shaw & Co first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 6 quarters.
  • D.E. Shaw & Co's Novelion Therapeutics Inc. Common Shares position peaked at $611K in Q4 2016.
  • 53 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q2 2018.

Based on D.E. Shaw & Co's 13F filing for Q2 2018, filed 14 Aug 2018.